ChemoCentryx, Inc. (CCXI)

Oncology Corporate Profile

Stock Performance

2.4000
-0.0700

HQ Location

850 Maude Avenue
Mountain View, CA 94043

Company Description

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer.

Website: http://www.chemocentryx.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
CCX872CCR2 inhibitorPancreatic cancerI
CCX650CXCR7 inhibitorGlioblastoma Multiforme (GBM)Preclinical

View additional information on product candidates here »

Pipeline image

Source


http://www.chemocentryx.com

Recent News Headlines

ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy (C3G)

3/22/2017 12:03 pm

[GlobeNewswire] - MOUNTAIN VIEW, Calif., March 22, 2017-- ChemoCentryx, Inc.,, a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, announced today that the ...

ChemoCentryx reports 4Q loss

3/14/2017 09:00 pm

ChemoCentryx reports 4Q loss

3/14/2017 09:00 pm

ChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial Results

3/14/2017 08:00 pm

[GlobeNewswire] - --Expanded Vifor Pharma partnership now totals $155 million in upfront cash commitments, $1.2 billion in potential milestone payments, plus substantial royalties on potential net sales--. --Initiated Phase ...

ChemoCentryx to Hold Fourth Quarter 2016 Financial Results Conference Call on Tuesday, March 14, 2017

3/1/2017 01:03 pm

[GlobeNewswire] - MOUNTAIN VIEW, Calif., March 01, 2017-- ChemoCentryx, Inc.,, today announced that the Company's fourth quarter 2016 financial results will be released after market close on Tuesday, March 14, 2017. ChemoCentryx ...

ChemoCentryx to Present at the Cowen and Company 37th Annual Health Care Conference

2/28/2017 01:03 pm

[GlobeNewswire] - MOUNTAIN VIEW, Calif., Feb. 28, 2017-- ChemoCentryx, Inc.,, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health ...

Vifor Pharma and ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal Diseases

2/14/2017 12:00 pm

[GlobeNewswire] - --ChemoCentryx retains all rights in the United States and China; Vifor Pharma gains additional marketing rights in Asia, including Japan and Middle Eastern markets--. --ChemoCentryx to receive additional ...

ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor CCX872 in Patients with Advanced Non-Resectable Pancreatic Cancer

1/20/2017 08:03 pm

[GlobeNewswire] - MOUNTAIN VIEW, Calif., Jan. 20, 2017-- ChemoCentryx, Inc., today announced the presentation of results from its immuno-oncology program at the American Society of Clinical Oncology 2017 Gastrointestinal ...

ChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the Nasdaq Entrepreneurial Center in San Francisco

1/20/2017 03:00 pm

[GlobeNewswire] - What: ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant ...

ChemoCentryx Provides Corporate Update Including Development Strategy for Lead Programs in Rare Renal Diseases

1/9/2017 12:03 pm

[GlobeNewswire] - --Company Initiates Phase III“ ADVOCATE” Clinical Trial for Complement Receptor Inhibitor Avacopan in ANCA Vasculitis; Development Path Outlined in Rare Kidney Disease for Chemokine Receptor Inhibitor‘ ...

ChemoCentryx to Present at the 35th Annual J.P. Morgan Healthcare Conference

1/4/2017 01:03 pm

[GlobeNewswire] - MOUNTAIN VIEW, Calif., Jan. 04, 2017-- ChemoCentryx, Inc.,, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 35 th Annual J.P. Morgan Healthcare ...